


Otsuka America Pharmaceutical, Inc.
and Lundbeck Cordially Invite You
to Attend

MOVING BEYOND PARTIAL RESPONSE IN MDD

Adding Adjunctive
REXULTI® (brexpiprazole) to an
Antidepressant for Your Appropriate
Adult Patients With Major Depressive
Disorder (MDD)



Antidepressant

REXULTI® (brexpiprazole)
+ Antidepressant



Presented by
Jason Carter, PharmD

Program Details
**Tuesday,
September 19, 2023**

Top Shell Grill
6080 Getwell Road
Southaven, Mississippi
38672

The Presentation Begins at
6:00 PM Central

**You Have Been Cordially Invited By
John Abadie**

Speaker is a paid consultant or employee
of Otsuka America Pharmaceutical, Inc.
and/or Lundbeck.

To Make a Reservation

Please call 901-409-4390 or email JOHN.ABADIE@OTSUKA-US.COM.
Please refer to Meeting ID number **ORT0118421** when making your
reservation.

Pre-registration to attend this program is encouraged. In accordance with updated
PhRMA guidelines, no Otsuka/Lundbeck-provided alcohol will be served at this program.

The Program Will Cover

- ▶ The increasing role primary care providers (PCPs) play in treating patients with depression
- ▶ Identifying patients with MDD who may be experiencing a partial response to their antidepressant and when augmenting with an atypical antipsychotic may help
- ▶ The clinical efficacy and safety data profile of REXULTI as an adjunctive therapy for adult patients with MDD
- ▶ A hypothetical patient profile to help identify adult patients who may be appropriate for treatment with REXULTI
- ▶ An overview of the pivotal clinical data for REXULTI as a treatment option for agitation associated with dementia due to Alzheimer's disease

The intended audience for this program is healthcare professionals (HCPs) involved in the treatment of adult patients with MDD, schizophrenia, or agitation associated with Alzheimer's dementia (AAD). This program is sponsored by Otsuka America Pharmaceutical, Inc. and Lundbeck. This invitation is nontransferable.

INDICATIONS

REXULTI is indicated for:

- Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
 - Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
 - Treatment of agitation associated with dementia due to Alzheimer's disease
- Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

(continued on next page ▶)

Please see accompanying FULL PRESCRIBING INFORMATION, including **BOXED WARNING**.